Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/62031
metadata.dc.identifier.doi: https://doi.org/10.56042/ijc.v62i6.2532
Title: In vitro and in silico studies on novel N-substituted-3,5-diaryl-pyrazoline derivatives as COX-2 inhibitors and anti-inflammatory agents
Authors: Bhadoriya, Upendra
Jain, Dinesh Kumar
Keywords: Heterocycles;Pyrazoline;Chalcone;Anti-Inflammatory;Cyclooxygenase-II
Issue Date: Jun-2023
Publisher: NIScPR-CSIR, India
Abstract: The presence of a reactive α,β-unsaturated keto group along with substituted aryl ring improves biological profile of pyrazoline nucleus. Considering this fact a study was planned to synthesize novel pyrazoline derivatives incorporated with chalcone backbone and their evaluation as COX-2 inhibitors and anti-inflammatory agents. Bovine serum albumin denaturation assay was used to measure in vitro anti-inflammatory activity. Molecular docking study was performed using Schrödinger-Maestro 9.0 molecular docking software and cyclooxygenase-2 (COX-II) receptor PDB ID: 4-COX. Some of the synthesized compounds showed remarkable anti-inflammatory potential. The compound (E)-3-(4-hydroxyphenyl)-1-(3-(4-hydroxyphenyl)-5-phenyl-4,5-dihydropyrazol-1-yl)prop-2-en-1-one 6d was found to be the most potent anti-inflammatory agents with 69.88% inhibition of protein denaturation. The outcome of docking study also supported results of in vitro anti-inflammatory activity and docking score for compound 6d was found to be –6.70379 which was comparable to the co-crystallized ligand. The results reveal that the synthesized compound can serve as potential lead for the development of novel anti-inflammatory agents.
Page(s): 627-633
ISSN: 2583-1321 (Online); 0019-5103 (Print)
Appears in Collections:IJC Vol.62(06) [June 2023]

Files in This Item:
File Description SizeFormat 
IJC 62 (06) 627-633.pdf754.96 kBAdobe PDFView/Open
IJC 62 (06) 627-633 Suppl. Data.pdf3.08 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.